The Food and Drug Administration Wednesday approved a drug developed Thousand Oaks-based Amgen Inc. to treat advanced colon cancer. Called Vectibix or by generic name panitumumab, the drug is administered intravenously twice a month. It could be ready as soon next month, the company said. Amgen has a handful of products on the oncology market, but treat only cancer treatment side effects such as anemia.